| taxon | Q16521 |
| P3088 | Catalogue of Life in Taiwan ID (old version) | 405399 |
| P3219 | Encyclopædia Universalis ID | virus-lassa |
| P7807 | ICD-11 ID (Foundation) | 401860716 |
| P7329 | ICD-11 ID (MMS) | XN0CU |
| P5055 | IRMNG ID | 11460147 |
| P3827 | JSTOR topic ID (archived) | lassa-virus |
| P486 | MeSH descriptor ID | D007836 |
| P672 | MeSH tree code | B04.820.480.500.070.100.500 |
| P2892 | UMLS CUI | C0023093 |
| P652 | UNII | AYO3YHR5BL |
| P183 | endemic to | Liberia | Q1014 |
| P1542 | has effect | Lassa fever | Q706845 |
| P4628 | ICTV virus genome composition | ssRNA(+/-) | Q44209519 |
| P171 | parent taxon | Arenavirus | Q2368907 |
| P225 | taxon name | Lassa virus | |
| P105 | taxon rank | species | Q7432 |
| Q37530422 | 25-Hydroxycholesterol Inhibition of Lassa Virus Infection through Aberrant GP1 Glycosylation |
| Q40040969 | A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses |
| Q46768300 | A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever |
| Q90629771 | A Lassa Virus Live-Attenuated Vaccine Candidate Based on Rearrangement of the Intergenic Region |
| Q35842756 | A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity |
| Q24813977 | A Promising Candidate for a Lassa Fever Vaccine |
| Q92102863 | A Review of Hearing Loss Associated with Zika, Ebola, and Lassa Fever |
| Q130037310 | A Salt Bridge and Disulfide Bond within the Lassa Virus Fusion Domain Are Required for the Initiation of Membrane Fusion |
| Q92987631 | A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge |
| Q42332110 | A case of Lassa fever. |
| Q42332863 | A case of Lassa fever. |
| Q34056433 | A case of Lassa fever: clinical and virological findings |
| Q34765142 | A case of Lassa fever: experience at St Thomas's Hospital. |
| Q40798873 | A case-control study of the clinical diagnosis and course of Lassa fever |
| Q91571461 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity |
| Q34495206 | A clinical guide to viral haemorrhagic fevers: Ebola, Marburg and Lassa |
| Q40397201 | A fatal case of Lassa fever in London, January 2009. |
| Q40779550 | A first Lassa fever from Sierra Leone treated in high security ward |
| Q36641764 | A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection |
| Q40908861 | A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. |
| Q33226128 | A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses |
| Q40569675 | A man with fatal Lassa fever following a stay in Sierra Leone |
| Q40885623 | A neutralization test survey for Lassa fever activity in Lassa, Nigeria |
| Q40845765 | A patient with Lassa fever from the Upper Volta, diagnosed in the Netherlands |
| Q40772339 | A plasma inhibitor of platelet aggregation in patients with Lassa fever |
| Q60941680 | A potent Lassa virus antiviral targets an arenavirus virulence determinant |
| Q24675684 | A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy |
| Q40798878 | A prospective study of the epidemiology and ecology of Lassa fever |
| Q30831264 | A rapid fluorometric assay for the proteolytic activity of SKI-1/S1P based on the surface glycoprotein of the hemorrhagic fever Lassa virus |
| Q36702610 | A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques |
| Q27473027 | A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins |
| Q35463993 | A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses |
| Q61797562 | A recombinant vesicular stomatitis-based Lassa fever vaccine elicits rapid and long-term protection from lethal Lassa virus infection in guinea pigs |
| Q27486129 | A serological survey of Lassa fever in Liberia |
| Q27865376 | A serological survey on viral haemorrhagic fevers in liberia |
| Q50238895 | A step on the path to a Lassa vaccine |
| Q40648344 | A survey for antibodies to Lassa virus among health workers in Nigeria |
| Q40710303 | A trial to produce an inactivated Lassa fever vaccine |
| Q92089097 | A vaccine based on recombinant modified Vaccinia Ankara containing the nucleoprotein from Lassa virus protects against disease progression in a guinea pig model |
| Q50240039 | A welcome mat for leprosy and Lassa fever |
| Q94048740 | A40 Estimation of Lassa virus emergence in Upper Guinea through a time-calibrated phylogeny |
| Q55246727 | Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods. |
| Q97414812 | Acidic pH Triggers Lipid Mixing Mediated by Lassa Virus GP |
| Q35915630 | Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike |
| Q56475780 | Acute Lassa Virus Encephalitis with Lassa Virus in the Cerebrospinal Fluid but Absent in the Blood: A Case Report with a Positive Outcome |
| Q33870918 | Acute abdominal pain in patients with lassa fever: Radiological assessment and diagnostic challenges |
| Q40852278 | Acute and chronic Lassa virus infection of Vero cells |
| Q40757577 | Acute sensorineural deafness in Lassa fever |
| Q90342717 | Adaptive genetic diversification of Lassa virus associated with the epidemic split of north-central Nigerian and non-Nigerian lineages |
| Q98502792 | Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity |
| Q26823627 | Advanced vaccine candidates for Lassa fever |
| Q50240204 | Aeromedical evacuation of patients with Lassa fever |
| Q40286565 | Aeromedical evacuation using an aircraft transit isolator of a patient with Lassa fever |
| Q39401357 | Algorithms in the diagnosis and management of exotic diseases. XIX. Major tropical viral infections: smallpox, yellow fever, and Lassa fever |
| Q50239728 | Allele frequencies of 15 STR loci of Tibetan lived in Tibet Lassa |
| Q47244680 | Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins |
| Q40444960 | Amino acids from both N-terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent membrane fusion and infectivity |
| Q38348049 | An N-terminal region of Lassa virus L protein plays a critical role in transcription but not replication of the virus genome |
| Q38378926 | An Outbreak of Ebola Virus Disease in the Lassa Fever Zone |
| Q128204621 | An atlas of gross and histologic lesions and immunohistochemical immunoreactivity during the temporal progression of aerosolized Lassa virus induced hemorrhagic fever in cynomolgus macaques |
| Q36698306 | An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. |
| Q40694425 | An evaluation of the possibility of obtaining an inactivated vaccine against Lassa fever |
| Q40782911 | An imported case of Lassa fever with late appearance of polyserositis |
| Q40932138 | An outbreak of Lassa fever on the Jos plateau, Nigeria, in January-February 1970. A preliminary report |
| Q38459804 | An update on Lassa virus |
| Q39287965 | Analysis of gene expression in Lassa virus-infected HuH-7 cells |
| Q30375851 | Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. |
| Q92821211 | Animal models for Lassa virus infection |
| Q40072945 | Annual Incidence of Lassa Virus Infection in Southern Mali |
| Q40822188 | Antibodies to Lassa and Lassa-like viruses in man and mammals in the Central African Republic |
| Q38884923 | Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions |
| Q39038809 | Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro |
| Q64360387 | Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses |
| Q35077253 | Arenaviruses other than Lassa virus |
| Q40116055 | As Ebola winds down, Lassa Fever reemerges yet again in West Africa |
| Q37443156 | Aseptic Meningitis Caused by Lassa Virus: Case Series Report. |
| Q33567793 | At Home with Mastomys and Rattus: Human-Rodent Interactions and Potential for Primary Transmission of Lassa Virus in Domestic Spaces |
| Q64230959 | Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1 Mice |
| Q40736230 | Audiometric comparison of Lassa fever hearing loss and idiopathic sudden hearing loss: evidence for viral cause |
| Q63916860 | Autophagy Promotes Infectious Particle Production of Mopeia and Lassa Viruses |
| Q47296347 | Axl can serve as entry factor for Lassa virus depending on the functional glycosylation of dystroglycan. |
| Q27486385 | Bacterial-based systems for expression and purification of recombinant Lassa virus proteins of immunological relevance |
| Q40729904 | Baculovirus expression of the glycoprotein gene of Lassa virus and characterization of the recombinant protein |
| Q52723914 | Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. |
| Q99589366 | Bayesian estimation of Lassa virus epidemiological parameters: Implications for spillover prevention using wildlife vaccination |
| Q37406952 | Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. |
| Q63915688 | Biochemical characterization of the Lassa virus L protein |
| Q38580722 | Biological species in Praomys (Mastomys) natalensis (Smith), a rodent carrier of Lassa virus and bubonic plague in Africa |
| Q113535216 | Bridging the gap: Using reservoir ecology and human serosurveys to estimate Lassa virus spillover in West Africa |
| Q39287984 | Broad-spectrum antiviral activity of small interfering RNA targeting the conserved RNA termini of Lassa virus |
| Q27665958 | Cap binding and immune evasion revealed by Lassa nucleoprotein structure |
| Q35770348 | Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report |
| Q40834862 | Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. |
| Q37247060 | Cell entry of Lassa virus induces tyrosine phosphorylation of dystroglycan |
| Q34545961 | Cellular factors required for Lassa virus budding |
| Q40381655 | Change in blood test after irradiation with high doses for inactivation of Lassa virus |
| Q50240443 | Characteristics of monoclonal antibodies against Lassa virus |
| Q43513558 | Characteristics of the immune response in mice immunized with the inactivated Lassa virus |
| Q39893565 | Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles |
| Q33558319 | Characterization of Lassa virus glycoprotein oligomerization and influence of cholesterol on virus replication |
| Q33798561 | Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein |
| Q37342505 | Characterization of lassa virus cell entry inhibitors: determination of the active enantiomer by asymmetric synthesis |
| Q37382482 | Characterization of the Lassa virus GP1 ectodomain shedding: implications for improved diagnostic platforms |
| Q40538323 | Characterization of the Lassa virus matrix protein Z: electron microscopic study of virus-like particles and interaction with the nucleoprotein (NP). |
| Q40509716 | Characterization of the interaction of lassa fever virus with its cellular receptor alpha-dystroglycan |
| Q99210783 | Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity |
| Q36020913 | Chimeric Mice with Competent Hematopoietic Immunity Reproduce Key Features of Severe Lassa Fever |
| Q38905532 | Cis- and cell-type-dependent trans-requirements for Lassa virus-like particle production |
| Q35957928 | Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus |
| Q54258792 | Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study. |
| Q39010248 | Clinical features of Lassa fever in Liberia |
| Q40477292 | Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with Pirital virus (Arenaviridae): a rodent model of Lassa fever. |
| Q33486013 | Clinical observations in 42 patients with Lassa fever. |
| Q40908853 | Clinical presentation of lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972 * |
| Q34692528 | Clinical virology of Lassa fever in hospitalized patients |
| Q40811789 | Clinical, epidemiologic, and therapeutic aspects of Lassa fever |
| Q40764019 | Comparative evaluation of the antiviral efficacy of virazole and ribamidil in experimental Lassa fever in monkeys |
| Q42125978 | Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis |
| Q45840274 | Comparison of Lassa, Mobala, and Ippy virus reactions by immunofluorescence test |
| Q34437676 | Completion of the Lassa fever virus sequence and identification of a RING finger open reading frame at the L RNA 5' End. |
| Q90068194 | Comprehensive Interactome Analysis Reveals that STT3B Is Required for N-Glycosylation of Lassa Virus Glycoprotein |
| Q47548092 | Computer aided epitope design as a peptide vaccine component against Lassa virus |
| Q50239975 | Conformational changes in Lassa viral proteins when exposed to antibodies and complement |
| Q111149688 | Conformational changes in Lassa virus L protein associated with promoter binding and RNA synthesis activity |
| Q39608675 | Conserved residues in Lassa fever virus Z protein modulate viral infectivity at the level of the ribonucleoprotein |
| Q33621077 | Constraints in the diagnosis and treatment of Lassa Fever and the effect on mortality in hospitalized children and women with obstetric conditions in a rural district hospital in Sierra Leone |
| Q40788654 | Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection |
| Q30222134 | Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012). |
| Q41919417 | Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016. |
| Q92525192 | Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization |
| Q45896218 | Correction: Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report |
| Q24794824 | Correction: Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus |
| Q58796446 | Critical role for cholesterol in Lassa fever virus entry identified by a novel small molecule inhibitor targeting the viral receptor LAMP1 |
| Q36648449 | Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus |
| Q92921743 | Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors |
| Q40116818 | Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z. |
| Q27675573 | Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding |
| Q40339621 | Current molecular epidemiology of Lassa virus in Nigeria |
| Q56909960 | Current research for a vaccine against Lassa hemorrhagic fever virus |
| Q33964796 | Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses |
| Q44106189 | DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs |
| Q51783196 | Deadly Lassa-fever outbreak tests Nigeria's revamped health agency. |
| Q45238531 | Deafness associated with Lassa fever |
| Q37572562 | Deciphering the glycosylome of dystroglycanopathies using haploid screens for lassa virus entry |
| Q39635009 | Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus |
| Q98513600 | Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time |
| Q52696613 | Design of peptide-based epitope vaccine and further binding site scrutiny led to groundswell in drug discovery against Lassa virus. |
| Q57045814 | Design of recombinant virus vaccines for Lassa fever |
| Q40273257 | Detection and antigenic characteristics of the recombinant nucleocapsid proteins of Lassa and Marburg viruses |
| Q93043698 | Detection of Antibody and Antigen for Lassa Virus Nucleoprotein in Monkeys from Southern Nigeria |
| Q37193428 | Detection of Lassa virus RNA in specimens from patients with Lassa fever by using the polymerase chain reaction |
| Q37267595 | Detection of Lassa virus antigens and Lassa virus-specific immunoglobulins G and M by enzyme-linked immunosorbent assay. |
| Q39517640 | Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. |
| Q35877121 | Detection of Lassa virus, Mali |
| Q38482027 | Detection of anti-Lassa antibodies in the Western Forest area of the Ivory Coast |
| Q109048250 | Determining Ancestry between Rodent- and Human-Derived Lassa Virus Sequences in Endemic Foci within West Africa: Indications of Reverse Zoonosis |
| Q89659025 | Determining Ancestry between Rodent- and Human-Derived Virus Sequences in Endemic Foci: Towards a More Integral Molecular Epidemiology of Lassa Fever within West Africa |
| Q41718140 | Determining Ribavirin's mechanism of action against Lassa virus infection |
| Q92564308 | Development and Evaluation of a One-Step Quantitative RT-PCR Assay for Detection of Lassa Virus |
| Q55039264 | Development and evaluation of antibody-capture immunoassays for detection of Lassa virus nucleoprotein-specific immunoglobulin M and G |
| Q40654114 | Development and study of immunoglobulins against Lassa fever |
| Q40648441 | Development and study of properties of immunoglobulins against Lassa fever |
| Q21563440 | Development of a new vaccine for the prevention of Lassa fever |
| Q39037568 | Development of a time-trend model for analyzing and predicting case-pattern of Lassa fever epidemics in Liberia, 2013-2017. |
| Q93028401 | Development of an RT-LAMP assay for the detection of Lassa viruses in southeast and south-central Nigeria |
| Q36095179 | Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever |
| Q55623988 | Diagnosing Lassa virus infection by tracking the antiviral response. |
| Q24550962 | Diagnosis and clinical virology of Lassa fever as evaluated by enzyme-linked immunosorbent assay, indirect fluorescent-antibody test, and virus isolation |
| Q36630621 | Diagnosis of Lassa fever and the isolation and management of patients |
| Q64246749 | Diagnostic applications for Lassa fever in limited-resource settings |
| Q30209669 | Diagnostic proficiency and reporting of Lassa fever by physicians in Osun State of Nigeria |
| Q41922464 | Diagnostics for Lassa Fever: Detecting Host Antibody Responses. |
| Q64246765 | Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings |
| Q91386563 | Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses |
| Q39302482 | Differential Immune Responses to New World and Old World Mammalian Arenaviruses |
| Q44697859 | Differentiation between two African arenaviruses (Lassa and Mozambique) by plaque assay |
| Q33501744 | Dimerization of tetherin is not essential for its antiviral activity against Lassa and Marburg viruses |
| Q49550626 | Discharge Criteria for Patient With Lassa Fever Infection |
| Q38924217 | Domain structure of Lassa virus L protein |
| Q59625358 | Dose-Response Model for Lassa Virus |
| Q64120063 | Dynamic Dystroglycan Complexes Mediate Cell Entry of Lassa Virus |
| Q40780110 | Dynamics of antigen and antibody accumulation in adult mice, infected with Lassa virus |
| Q92444873 | E3 Ligase ITCH Interacts with the Z Matrix Protein of Lassa and Mopeia Viruses and Is Required for the Release of Infectious Particles |
| Q33383772 | Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys |
| Q40210245 | Early blood profiles of virus infection in a monkey model for Lassa fever. |
| Q40181137 | Early diagnosis of Lassa fever by reverse transcription-PCR. |
| Q40820096 | Early diagnosis of human Lassa fever by ELISA detection of antigen and antibody |
| Q40349669 | Early-onset sensorineural hearing loss in Lassa fever. |
| Q90350597 | Editorial overview: Lassa virus |
| Q67513129 | Editorial: Lassa and marburg viruses |
| Q98619163 | Effect of Strain Variations on Lassa Virus Z Protein-Mediated Human RIG-I Inhibition |
| Q40830494 | Effect of environmental factors on aerosol-induced Lassa virus infection |
| Q40777147 | Effect of immunosuppression on the development and outcome of an acute infection in mice caused by administration of the Lassa virus |
| Q38616086 | Effect of storage temperature on the stability of Lassa virus complement-fixing antigen |
| Q33808492 | Effective vaccine for lassa fever |
| Q38565357 | Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever |
| Q39595245 | Efficient rescue of recombinant Lassa virus reveals the influence of S segment noncoding regions on virus replication and virulence |
| Q40770353 | Electrocardiographic abnormalities in patients with Lassa fever |
| Q36451581 | Electron microscopic study of Lassa virus |
| Q47546968 | Emergence of Lassa Fever Disease in Northern Togo: Report of Two Cases in Oti District in 2016. |
| Q40107887 | Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influe |
| Q21245085 | Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection |
| Q38521946 | Endemic Lassa fever in Liberia. I. Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia |
| Q40831036 | Endemic Lassa fever in Liberia. II. Serological and virological findings in hospital patients |
| Q40821588 | Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates |
| Q40821582 | Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization |
| Q40830945 | Endemic Lassa fever in Liberia. V. Distribution of Lassa virus activity in Liberia: hospital staff surveys |
| Q40830939 | Endemic Lassa fever in Liberia. VI. Village serological surveys for evidence of Lassa virus activity in Lofa County, Liberia |
| Q39522938 | Engaging Market Traders in Lassa Fever Campaign: Assessment of Knowledge and Risk Behaviour |
| Q35826698 | Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. |
| Q34676766 | Enhanced methods for unbiased deep sequencing of Lassa and Ebola RNA viruses from clinical and biological samples |
| Q40828683 | Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys |
| Q24575400 | Environmental-mechanistic modelling of the impact of global change on human zoonotic disease emergence: a case study of Lassa fever |
| Q47169555 | Epidemic preparedness and management: A guide on Lassa fever outbreak preparedness plan |
| Q40871185 | Epidemiological aspect of the 1976 Pankshin Lassa fever outbreak |
| Q40800921 | Epidemiology and control of Lassa fever |
| Q40892882 | Epidemiology of Lassa fever |
| Q45847112 | Epitope mapping of the Lassa virus nucleoprotein using monoclonal anti-nucleocapsid antibodies |
| Q56960410 | Etymologia:Lassa[lah sə]virus |
| Q64359225 | Evaluating Temperature Sensitivity of Vesicular Stomatitis Virus-Based Vaccines |
| Q40511063 | Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein |
| Q35870592 | Evaluation of Lassa antiviral compound ST-193 in a guinea pig model |
| Q36581311 | Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model |
| Q40714616 | Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection |
| Q40790240 | Evidence against high contagiousness of Lassa fever |
| Q34057974 | Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness. |
| Q40811784 | Evolutionary biology of a Lassa virus complex |
| Q38650789 | Exchange transfusion of a patient with fulminant Lassa fever |
| Q40189585 | Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response |
| Q40862101 | Exotic infectious diseases: Lassa fever. |
| Q40842635 | Experimental Infection of Rhesus Monkeys with Lassa Virus and a Closely Related Arenavirus, Mozambique Virus |
| Q40751366 | Experimental Lassa fever in hamadryas baboons |
| Q45894573 | Experimental Lassa fever virus infection successfully treated with ribavirin |
| Q40757315 | Experimental Lassa infection in monkeys and its treatment with ribamidil |
| Q42633699 | Experimental Lassa virus infection in the squirrel monkey |
| Q46683420 | Experimental evaluation of the pathogenicity of Lassa virus variants |
| Q95275894 | Exploring Lassa Virus Proteome to Design a Multi-epitope Vaccine Through Immunoinformatics and Immune Simulation Analyses |
| Q41922424 | Expression and X-Ray Structural Determination of the Nucleoprotein of Lassa Fever Virus |
| Q44843720 | Expression of Lassa virus nucleocapsid gene fragments in bacteria |
| Q44120366 | Expression of Lassa virus nucleocapsid protein segments in bacteria: purification of high-level expression products and their application in antibody detection |
| Q40765925 | Expression of the Lassa virus nucleocapsid protein in insect cells infected with a recombinant baculovirus: application to diagnostic assays for Lassa virus infection |
| Q50240790 | Factors affecting plaque formation by Lassa virus in Vero cells |
| Q40654119 | False-positive reactions in laboratory diagnosis of Lassa, Marburg, and Ebola viral hemorrhagic fevers and AIDS |
| Q41920062 | Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever |
| Q52590886 | Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever. |
| Q33290686 | Fluctuation of abundance and Lassa virus prevalence in Mastomys natalensis in Guinea, West Africa |
| Q128812821 | From Social Determinants of Health Actions to Fight against the Lassa Virus Hemorrhagic Fever Epidemic in Tchaourou Commune in Benin, 2018 |
| Q35826301 | Functional interferon system is required for clearance of lassa virus |
| Q40856905 | Further comment on Lassa fever |
| Q90833652 | GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus |
| Q39034666 | Gairo virus, a novel arenavirus of the widespread Mastomys natalensis: Genetically divergent, but ecologically similar to Lassa and Morogoro viruses |
| Q60048628 | Genetic characterization of Lassa virus strains isolated from 2012 to 2016 in southeastern Nigeria |
| Q24525321 | Genetic diversity among Lassa virus strains |
| Q44470764 | Genetic variation among Lassa and Lassa-related arenaviruses analysed by T1-oligonucleotide mapping |
| Q37643724 | Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate |
| Q37277649 | Genome Sequence of Lassa Virus Isolated from the First Domestically Acquired Case in Germany |
| Q35701103 | Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever |
| Q57454077 | Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018 |
| Q35248863 | Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man |
| Q35068062 | Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali |
| Q34484140 | Guidance for contact tracing of cases of Lassa fever, Ebola or Marburg haemorrhagic fever on an airplane: results of a European expert consultation |
| Q64261683 | HLA-C-restricted viral epitopes are associated with an escape mechanism from KIR2DL2 NK cells in Lassa virus infection |
| Q40847249 | Haemorrhagic fever in Gabon. I. Incidence of Lassa, Ebola and Marburg viruses in Haut-Ogooué. |
| Q36630633 | Handling patients with suspected Lassa fever entering Great Britain |
| Q33448183 | Hematologic dysfunction in Lassa fever |
| Q33845111 | Hemorrhagic (Marburg, Ebola, Lassa, and Bolivian) fevers: epidemiology, clinical pictures, and treatment |
| Q90109832 | High crossreactivity of human T cell responses between Lassa virus lineages |
| Q27681674 | High-Resolution Structure of the N-Terminal Endonuclease Domain of the Lassa Virus L Polymerase in Complex with Magnesium Ions |
| Q69462886 | Histopathological diagnosis of hepatitis due to Lassa virus |
| Q36029406 | Historical Lassa fever reports and 30-year clinical update |
| Q40903597 | Hoosiers abroad--report of a case of Lassa fever |
| Q34031974 | Hospital-based surveillance for Lassa fever in Edo State, Nigeria, 2005-2008. |
| Q57798235 | Host proteins identified in extracellular viral particles as targets for broad-spectrum antiviral inhibitors |
| Q60907586 | Host-Driven Phosphorylation Appears to Regulate the Budding Activity of the Lassa Virus Matrix Protein |
| Q95854076 | Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea |
| Q34530240 | Housing equity for health equity: a rights-based approach to the control of Lassa fever in post-war Sierra Leone |
| Q33365688 | Human antibody pieces together the puzzle of the trimeric Lassa virus surface antigen |
| Q35140402 | Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus |
| Q40040779 | Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever |
| Q39517644 | Hunting of peridomestic rodents and consumption of their meat as possible risk factors for rodent-to-human transmission of Lassa virus in the Republic of Guinea |
| Q50239523 | Hydrogen peroxide vapour decontamination of a critical care unit room used to treat a patient with Lassa fever |
| Q40190048 | Hyperglycemic crisis precipitated by Lassa fever in a patient with previously undiagnosed type 2 diabetes mellitus |
| Q45840277 | Identification of Ippy as a Lassa-fever-related virus |
| Q44171083 | Identification of Lassa fever virus infection with recombinant nucleocapsid protein antigen |
| Q41009844 | Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor |
| Q90765231 | Identification of Residues in Lassa Virus Glycoprotein Subunit 2 That Are Critical for Protein Function |
| Q50424749 | Identification of a Novel Consensus Sequence at the Cleavage Site of the Lassa Virus Glycoprotein |
| Q92890803 | Identification of a clinical compound losmapimod that blocks Lassa virus entry |
| Q39597992 | Identification of a novel consensus sequence at the cleavage site of the Lassa virus glycoprotein |
| Q43551694 | Identification of a protective epitope--a fragment of Lassa virus nucleoprotein |
| Q28291275 | Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus |
| Q35826584 | Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry |
| Q40791053 | Identification of messenger RNA for nucleocapsid protein of Lassa virus in infected cells |
| Q35024149 | Identification of protective Lassa virus epitopes that are restricted by HLA-A2. |
| Q96304535 | Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry |
| Q38064284 | Immune responses and Lassa virus infection |
| Q58097208 | Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques |
| Q50240305 | Immunization of rabbits with Lassa virus |
| Q30238887 | Immunobiology of Ebola and Lassa virus infections |
| Q40581138 | Immunogenic and protective characteristics of recombinant Lassa virus NP protein |
| Q91882087 | Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques |
| Q38616381 | Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections |
| Q40076535 | Imported Case of Lassa Fever in Sweden With Encephalopathy and Sensorineural Hearing Deficit |
| Q40559139 | Imported Lassa fever in Germany: surveillance and management of contact persons |
| Q35804577 | Imported Lassa fever, Pennsylvania, USA, 2010 |
| Q40524798 | Imported Lassa fever--New Jersey, 2004. |
| Q44028870 | Imported Lassa fever--reexamining the algorithms |
| Q35645720 | Imported Lassa fever: A report of 2 cases in Ghana |
| Q37064973 | Imported lassa fever in Germany: molecular characterization of a new lassa virus strain |
| Q39323126 | Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. |
| Q58109386 | Improving the Breadth of the Host's Immune Response to Lassa Virus |
| Q40129746 | In silico prediction of B- and T- cell epitope on Lassa virus proteins for peptide based subunit vaccine design |
| Q94592124 | In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever |
| Q40734123 | Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys |
| Q44088999 | Inactivating Lassa and Marburg/Ebola viruses |
| Q34057056 | Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation |
| Q40877230 | Inclusion of Lassa fever and other forms of African viral hemorrhagic fever in group A |
| Q64073946 | Increase in Lassa Fever Cases in Nigeria, January-March 2018 |
| Q40810114 | Indirect immunoenzyme method for the laboratory diagnosis of Lassa and Ebola hemorrhagic fevers |
| Q40900391 | Indirect immunofluorescence for the diagnosis of Lassa fever infection |
| Q33850032 | Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses |
| Q24294470 | Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin |
| Q36753696 | Influence of RNA Binding on the Structure and Dynamics of the Lassa Virus Nucleoprotein |
| Q24652263 | Inhibition of Lassa and Marburg virus production by tetherin |
| Q39468140 | Inhibition of Lassa virus and Ebola virus infection in host cells treated with the kinase inhibitors genistein and tyrphostin |
| Q33458341 | Inhibition of Lassa virus glycoprotein cleavage and multicycle replication by site 1 protease-adapted alpha(1)-antitrypsin variants |
| Q36509774 | Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus |
| Q50240604 | Inhibition of the accumulation of the Lassa virus in Vero cells by immune gamma globulin and complement |
| Q112285887 | Inoculation route-dependent Lassa virus dissemination and shedding dynamics in the natural reservoir - Mastomys natalensis |
| Q40207301 | Insight into the binding modes of Lassa nucleoprotein complexed with ssRNA by molecular dynamic simulations and free energy calculations |
| Q91541344 | Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development |
| Q35634369 | International external quality assessment study for molecular detection of Lassa virus |
| Q46851852 | Isolated case of Lassa fever in Zaria, Northern Nigeria |
| Q45811817 | Isolation and Antigenic Characterization of Lassa Virus |
| Q27485975 | Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa |
| Q40804983 | Journal of Infection Control Nursing. Nursing the isolated patient: Lassa fever |
| Q40815501 | Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys |
| Q38782251 | Knowledge Attitude and Practices Toward Lassa Fever Control and Prevention Among Residents of Ile-Ife, Southwest Nigeria |
| Q40049253 | Knowledge and attitudes of community volunteers on Lassa and Ebola viral haemorrhagic fevers in the Donga Department (North Benin) |
| Q38919182 | Knowledge of Secondary School Children in Edo State on Lassa Fever and its Implications for Prevention and Control |
| Q46036081 | Knowledge of health care workers and ability of healthcare facilities in preventing of Ebola virus diseases/lassa fever in Benin. |
| Q36131701 | LASSA: Emotion Detection via Information Fusion |
| Q39238911 | Laboratory Diagnosis of Lassa Fever |
| Q42725695 | Laboratory diagnosis of Lassa fever, liberia |
| Q47117332 | Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments |
| Q36718802 | Lassa Fever in Pregnancy: Report of 2 Cases Seen at the University College Hospital, Ibadan |
| Q39032336 | Lassa Virus Cell Entry Reveals New Aspects of Virus-Host Cell Interaction |
| Q37073355 | Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis. |
| Q94954969 | Lassa Virus Genetics |
| Q40056797 | Lassa Virus Reverse Genetics |
| Q36726640 | Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali |
| Q64073768 | Lassa Virus Targeting of Anterior Uvea and Endothelium of Cornea and Conjunctiva in Eye of Guinea Pig Model |
| Q45805861 | Lassa Virus Z Protein Is a Matrix Protein and Sufficient for the Release of Virus-Like Particles. |
| Q89685654 | Lassa Virus but Not Highly Pathogenic New World Arenaviruses Restrict Immunostimulatory dsRNA Accumulation During Infection |
| Q42400002 | Lassa Virus in Multimammate Rats, Côte d'Ivoire, 2013 |
| Q92314633 | Lassa Virus in Pygmy Mice, Benin, 2016-2017 |
| Q71927295 | Lassa Virus: A New Disease of Man? |
| Q64073517 | Lassa and Crimean-Congo Hemorrhagic Fever Viruses, Mali |
| Q38405014 | Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. |
| Q34515519 | Lassa and Marburg viruses elicit distinct host transcriptional responses early after infection |
| Q38571526 | Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression |
| Q40771788 | Lassa and Mozambique viruses: cross protection in experiments on mice and action of immunosuppressants on experimental infections |
| Q40856910 | Lassa fever |
| Q40920968 | Lassa fever |
| Q40616836 | Lassa fever |
| Q40812019 | Lassa fever |
| Q46338655 | Lassa fever |
| Q27478014 | Lassa fever |
| Q40874440 | Lassa fever (LF) and Marburg disease (MVD): occurrences, origins and diagnoses |
| Q40892425 | Lassa fever (arenaviruses) as a public health problem |
| Q40880868 | Lassa fever (author's transl) |
| Q40908308 | Lassa fever (review of the literature) |
| Q35207231 | Lassa fever - full recovery without ribavarin treatment: a case report |
| Q40920544 | Lassa fever A study of 23 hospital cases |
| Q40920538 | Lassa fever Epidemiological aspects of the 1970 epidemic, Jos, Nigeria |
| Q40877008 | Lassa fever and Marburg disease |
| Q40904967 | Lassa fever and Marburg virus disease. |
| Q40818523 | Lassa fever and pregnancy. |
| Q50239050 | Lassa fever and ribavirin |
| Q44577390 | Lassa fever and sudden hearing loss |
| Q40871179 | Lassa fever antibodies in hospital personnel in the Plateau State of Nigeria |
| Q33164345 | Lassa fever associated with effusive constrictive pericarditis and bilateral atrioventricular annular constriction: a case report |
| Q33843936 | Lassa fever encephalopathy: Lassa virus in cerebrospinal fluid but not in serum |
| Q40733081 | Lassa fever encephalopathy: clinical and laboratory findings |
| Q98157244 | Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus |
| Q50241367 | Lassa fever in Britain: an imported case |
| Q40562995 | Lassa fever in Guinea: I. Epidemiology of human disease and clinical observations |
| Q39644927 | Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals |
| Q40827263 | Lassa fever in London: environmental health aspects. |
| Q53701875 | Lassa fever in Nigeria: the great unknown. |
| Q27485967 | Lassa fever in Onitsha, East Central State, Nigeria in 1974 |
| Q24674837 | Lassa fever in Panguma Hospital, Sierra Leone, 1973-6 |
| Q38041654 | Lassa fever in West Africa: evidence for an expanded region of endemicity |
| Q34003112 | Lassa fever in West African sub-region: an overview |
| Q40847066 | Lassa fever in children |
| Q40811435 | Lassa fever in children in Sierra Leone, West Africa |
| Q24290732 | Lassa fever in post-conflict sierra leone |
| Q34209979 | Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. |
| Q34209987 | Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases |
| Q40757616 | Lassa fever in the United States. Investigation of a case and new guidelines for management |
| Q46553362 | Lassa fever is unheralded problem in West Africa |
| Q38503161 | Lassa fever or lassa hemorrhagic fever risk to humans from rodent-borne zoonoses |
| Q21231955 | Lassa fever presenting as acute abdomen: a case series |
| Q40883713 | Lassa fever surveillance: the need for better communication |
| Q34310006 | Lassa fever vaccine |
| Q40921142 | Lassa fever virological and serological studies |
| Q45832382 | Lassa fever virus in Senegal |
| Q27472584 | Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice |
| Q39674533 | Lassa fever virus: properties and characteristics |
| Q27478160 | Lassa fever, Marburg and Ebola virus diseases and other exotic diseases: is there a risk to Canada? |
| Q43188849 | Lassa fever, Nigeria, 2003 and 2004. |
| Q42725667 | Lassa fever, Nigeria, 2005-2008 |
| Q40932147 | Lassa fever, a new virus disease of man from West Africa. 3. Isolation and characterization of the virus |
| Q34204840 | Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings |
| Q33467975 | Lassa fever, a new virus disease of man from West Africa. II. Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease |
| Q40932143 | Lassa fever, a new virus disease of man from West Africa. IV. Electron microscopy of Vero cell cultures infected with Lassa virus |
| Q40794671 | Lassa fever, on-going problems and prospects |
| Q40887382 | Lassa fever--a new and contagious exotic imported disease |
| Q40874711 | Lassa fever--an autopsy report from the eastern part of Nigeria |
| Q40789485 | Lassa fever--first case diagnosed in Israel |
| Q40798884 | Lassa fever--new issues raised by field studies in West Africa |
| Q50104833 | Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden |
| Q27472810 | Lassa fever. |
| Q34694588 | Lassa fever. Effective therapy with ribavirin |
| Q45842013 | Lassa fever: 10 years on. |
| Q46680900 | Lassa fever: a new appraisal. |
| Q51333133 | Lassa fever: another threat from West Africa. |
| Q40871191 | Lassa fever: clinical symptoms and laboratory diagnosis |
| Q33822092 | Lassa fever: epidemiology, clinical features, and social consequences |
| Q40863014 | Lassa fever: epidemiology, symptomatology, management and prognosis |
| Q40788225 | Lassa fever: epidemiology, therapy and vaccine development. |
| Q34095391 | Lassa fever: immuno-epidemiological approach to the study of an endemic viral haemorrhagic fever |
| Q33732750 | Lassa fever: implications of T-cell immunity for vaccine development |
| Q40880144 | Lassa fever: response to an imported case |
| Q27477741 | Lassa fever: retrospective diagnosis of two patients seen in Great Britain in 1971 |
| Q24647130 | Lassa fever: review of epidemiology and epizootiology |
| Q35369649 | Lassa fever: review of virology, immunopathogenesis, and algorithms for control and therapy |
| Q43161212 | Lassa fever: the challenges of curtailing a deadly disease. |
| Q40771108 | Lassa fever: the first confirmed case imported into Canada |
| Q28744660 | Lassa hemorrhagic fever in a late term pregnancy from northern Sierra Leone with a positive maternal outcome: case report |
| Q27485976 | Lassa immune serum |
| Q46390141 | Lassa letter |
| Q34222970 | Lassa serology in natural populations of rodents and horizontal transmission |
| Q35919691 | Lassa virus |
| Q40560383 | Lassa virus |
| Q91831618 | Lassa virus RNA detection from suspected cases in Nigeria, 2011-2017 |
| Q40008957 | Lassa virus Z protein is a matrix protein and sufficient for the release of virus-like particles [corrected]. |
| Q59351260 | Lassa virus activates myeloid dendritic cells but suppresses their ability to stimulate T cells |
| Q39193599 | Lassa virus activity in Guinea: distribution of human antiviral antibody defined using enzyme-linked immunosorbent assay with recombinant antigen |
| Q40871636 | Lassa virus antibodies in hospital personnel in western Liberia |
| Q99212495 | Lassa virus antigen distribution and inflammation in the ear of infected strain 13/N guinea pigs |
| Q90528578 | Lassa virus circulating in Liberia: a retrospective genomic characterisation |
| Q40904016 | Lassa virus disease |
| Q61805002 | Lassa virus diversity and feasibility for universal prophylactic vaccine |
| Q45700668 | Lassa virus glycoprotein signal peptide displays a novel topology with an extended endoplasmic reticulum luminal region |
| Q59360283 | Lassa virus glycoprotein: stopping a moving target |
| Q44525484 | Lassa virus glycoproteins: antigenic and immunogenic properties of synthetic peptides to GP1. |
| Q40893889 | Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic |
| Q40809779 | Lassa virus hepatitis: a study of fatal Lassa fever in humans |
| Q36630658 | Lassa virus infection in Mastomys natalensis in Sierra Leone. Gross and microscopic findings in infected and uninfected animals |
| Q37834584 | Lassa virus infection in Nigeria: clinical perspective overview. |
| Q35857273 | Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues |
| Q33976118 | Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells |
| Q40861784 | Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin |
| Q36109574 | Lassa virus isolates from Mali and the Ivory Coast represent an emerging fifth lineage |
| Q40903379 | Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone |
| Q40817399 | Lassa virus lethality for inbred mice |
| Q38959283 | Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages |
| Q39229840 | Lassa virus-infected rodents in refugee camps in Guinea: a looming threat to public health in a politically unstable region |
| Q34322342 | Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever |
| Q40514888 | Lassa virus: seroepidemiological survey of rodents caught in Ekpoma and environs |
| Q40873270 | Lassa, Marbourg and Ebola viruses: new features of African tropical pathology. II. Epidemiology. Public health problems (author's transl) |
| Q42929014 | Lassa, Marburg and Ebola: newly described African fevers |
| Q38886667 | Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors |
| Q34996570 | Lead optimization of an acylhydrazone scaffold possessing antiviral activity against Lassa virus |
| Q41919409 | Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers |
| Q40147436 | Lessons learnt from the management of a case of Lassa fever and follow-up of nosocomial primary contacts in Nigeria during Ebola virus disease outbreak in West Africa |
| Q90287254 | Lethal Infection of Lassa Virus Isolated from a Human Clinical Sample in Outbred Guinea Pigs without Adaptation |
| Q39347483 | Letter: Lassa by letter |
| Q50241214 | Letter: Lassa fever |
| Q40602416 | Low levels of interleukin-8 and interferon-inducible protein-10 in serum are associated with fatal infections in acute Lassa fever |
| Q50240659 | Lung uptake of Tc-99m-tin colloid in a patient with Lassa fever |
| Q37912497 | Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. |
| Q50240522 | Management of Lassa fever |
| Q35083835 | Management of Lassa fever in European countries. |
| Q41919414 | Management of a Lassa fever outbreak, Rhineland-Palatinate, Germany, 2016. |
| Q50239851 | Management of a patient with Lassa fever to prevent transmission |
| Q44369524 | Managing Lassa fever |
| Q46643691 | Mapping of Lassa fever cases in post-conflict Liberia, 2008-2012: a descriptive and categorical analysis of age, gender and seasonal pattern |
| Q40059403 | Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses |
| Q27001682 | Mapping the zoonotic niche of Lassa fever in Africa |
| Q35221855 | Mapping transmission risk of Lassa fever in West Africa: the importance of quality control, sampling bias, and error weighting. |
| Q40870804 | Marburg, Ebole and Lassa virus infections |
| Q38514103 | Marburg, Lassa and Ebola viral hemorrhagic fevers (author's transl) |
| Q40874609 | Marburg, Lassa and Ebola virus as cause of hemorrhagic fever |
| Q90799792 | Markov State Model of Lassa Virus Nucleoprotein Reveals Large Structural Changes during the Trimer to Monomer Transition |
| Q35793687 | Mastomys natalensis and Lassa fever, West Africa |
| Q45372759 | Maturation cleavage within the ectodomain of Lassa virus glycoprotein relies on stabilization by the cytoplasmic tail |
| Q41929865 | Metabolomics analyses identify platelet activating factors and heme breakdown products as Lassa fever biomarkers |
| Q37252856 | Mice lacking functional STAT1 are highly susceptible to lethal infection with Lassa virus |
| Q53687971 | Mitigating the risks of global spread of Lassa fever at the 2018 Hajj pilgrimage. |
| Q44089004 | Modifications to indirect immunofluorescence tests on Lassa, Marburg, and Ebola material |
| Q38875186 | Molecular Mechanism for LAMP1 Recognition by Lassa Virus |
| Q40463178 | Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. |
| Q45828963 | Molecular cloning of Lassa virus RNA: nucleotide sequence and expression of the nucleocapsid protein gene |
| Q90171894 | Molecular confirmation and phylogeny of Lassa fever virus in Benin Republic 2014-2016 |
| Q40108671 | Molecular confirmation of Lassa fever imported into Ghana |
| Q21092277 | Molecular diagnostics for lassa fever at Irrua specialist teaching hospital, Nigeria: lessons learnt from two years of laboratory operation |
| Q100436899 | Monitoring of Lassa virus infection in suspected and confirmed cases in Ondo State, Nigeria |
| Q32061750 | Monitoring of clinical and laboratory data in two cases of imported Lassa fever |
| Q129290415 | Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus |
| Q51787327 | Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria. |
| Q28602816 | Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits |
| Q51145289 | Movement Patterns of Small Rodents in Lassa Fever-Endemic Villages in Guinea. |
| Q40040975 | Moving Lassa Fever Research and Care Into the 21st Century |
| Q36667058 | Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. |
| Q40628180 | Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein |
| Q38662402 | Mutational Analysis of Lassa Virus Glycoprotein Highlights Regions Required for Alpha-Dystroglycan Utilization |
| Q24673622 | Mutational analysis of the lassa virus promoter |
| Q39052863 | Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome |
| Q45813493 | Mystery Virus from Lassa |
| Q40287006 | NK cells are strongly activated by Lassa and Mopeia virus-infected human macrophages in vitro but do not mediate virus suppression |
| Q40406254 | NMR assignment of the arenaviral protein Z from Lassa fever virus |
| Q28833686 | New Hosts of The Lassa Virus |
| Q49819995 | New Lineage of Lassa Virus, Togo, 2016 |
| Q92141641 | New methodologies for the estimation of population vulnerability to diseases: a case study of Lassa fever and Ebola in Nigeria and Sierra Leone |
| Q34744278 | New opportunities for field research on the pathogenesis and treatment of Lassa fever |
| Q51782811 | Nigeria hit by unprecedented Lassa fever outbreak. |
| Q40803378 | No evidence for increased risk of Lassa fever infection in hospital staff |
| Q33612974 | No measurable adverse effects of Lassa, Morogoro and Gairo arenaviruses on their rodent reservoir host in natural conditions |
| Q63916866 | Non-Pathogenic Mopeia Virus Induces More Robust Activation of Plasmacytoid Dendritic Cells than Lassa Virus |
| Q34561551 | Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses |
| Q43964345 | Nucleotide sequence of the S RNA of Lassa virus (Nigerian strain) and comparative analysis of arenavirus gene products |
| Q45286863 | Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. |
| Q45662661 | Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones |
| Q24599583 | On the front lines of Lassa fever |
| Q40099564 | Outbreak of lassa fever in Nigeria: measures for prevention and control |
| Q41927480 | Oxidation-sensitive polymersomes as vaccine nanocarriers enhance humoral responses against Lassa virus envelope glycoprotein |
| Q123252560 | Passive Transfer of Animal-Derived Polyclonal Hyperimmune Antibodies Provides Protection of Mice from Lethal Lassa Virus Infection |
| Q37083078 | Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. |
| Q39725716 | Pathobiology of Lassa fever |
| Q24613450 | Pathogenesis of Lassa fever |
| Q35014564 | Pathogenesis of Lassa fever in cynomolgus macaques |
| Q36941000 | Pathogenesis of Lassa fever virus infection: I. Susceptibility of mice to recombinant Lassa Gp/LCMV chimeric virus |
| Q40598251 | Pathogenesis of Lassa virus infection in guinea pigs. |
| Q113277000 | Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys |
| Q38663795 | Pathogenesis of viral hemorrhagic fevers: Rift Valley fever and Lassa fever contrasted |
| Q43549544 | Pathogenic Machupo and Lassa arenaviruses: the biochemical properties of virion RNA and proteins |
| Q40815386 | Pathogenicity of the Lassa virus for laboratory mice |
| Q35885605 | Pathologic and virologic study of fatal Lassa fever in man. |
| Q40842412 | Pathology of Lassa virus infection in the rhesus monkey. |
| Q40800926 | Pathophysiology and treatment of Lassa fever. |
| Q43255015 | Patients with suspected Lassa fever in London during 1984. |
| Q45758338 | Patients with suspected Lassa fever in London during 1984. |
| Q47126357 | Patients with suspected Lassa fever in London during 1984. |
| Q40813771 | Patients with suspected Lassa fever in London during 1984: problems in their management at St Thomas's Hospital |
| Q39804781 | Pediatric Lassa fever: a review of 33 Liberian cases. |
| Q46693428 | People with Lassa fever. Interview by Anne Gulland |
| Q40348606 | Persistence in darkness of virulent alphaviruses, Ebola virus, and Lassa virus deposited on solid surfaces |
| Q90280708 | Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus) |
| Q92623299 | Phylogeography of Lassa Virus in Nigeria |
| Q40844623 | Physical and chemical methods of inactivating Lassa virus |
| Q34055826 | Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses |
| Q40799148 | Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever |
| Q40770926 | Plasma from patients with severe Lassa fever profoundly modulates f-met-leu-phe induced superoxide generation in neutrophils |
| Q38914377 | Poor housing quality increases risk of rodent infestation and Lassa fever in refugee camps of Sierra Leone |
| Q40830771 | Possible approaches to a vaccine against Lassa fever |
| Q39388305 | Postexposure prophylaxis for Lassa fever: Experience from a recent outbreak in Nigeria |
| Q63743492 | Pre-clinical development of a vaccine against Lassa fever |
| Q40844014 | Preclinical evaluation of monkeys of a ribavirin regimen proposed for use in Lassa fever patients |
| Q93544681 | Preparation and Use of Erythrocyte-Globulin Conjugates to Lassa Virus in Reversed Passive Hemagglutination and Inhibition |
| Q45844585 | Preparation and biochemical characterization of Lassa virus subvirion fractions |
| Q40230376 | Preparation and use of erythrocyte-globulin conjugates to Lassa virus in reversed passive hemagglutination and inhibition |
| Q126394588 | Preparation and use of erythrocyte-globulin conjugates to Lassa virus in reversed passive hemagglutination and inhibition |
| Q63572872 | Prevalence and Incidence of Lassa Virus Infection in Southern Mali |
| Q33516227 | Prevalence and risk factors of Lassa seropositivity in inhabitants of the forest region of Guinea: a cross-sectional study |
| Q38696655 | Prevalence of Lassa Virus Disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area |
| Q40046048 | Prevalence of Lassa virus among rodents trapped in three South-South States of Nigeria |
| Q40381451 | Prevention of lassa Fever in Nigeria |
| Q40899334 | Problems of clinical diagnosis and therapy of a new arena virus infection (Lassa fever) |
| Q37464889 | Production of CXC and CC chemokines by human antigen-presenting cells in response to Lassa virus or closely related immunogenic viruses, and in cynomolgus monkeys with lassa fever |
| Q50239976 | Production of immune mediators, induced by Lassa virus, in a human mononuclear cell culture |
| Q37934045 | Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses |
| Q92455264 | Protection From Lethal Lassa Disease Can Be Achieved Both Before and After Virus Exposure by Administration of Single-Cycle Replicating Lassa Virus Replicon Particles |
| Q40839520 | Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin |
| Q40773394 | Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus |
| Q45894483 | Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus |
| Q33829701 | Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene |
| Q39560339 | RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene |
| Q39323117 | Rapid and specific detection of Lassa virus by reverse transcription-PCR coupled with oligonucleotide array hybridization |
| Q27471311 | Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. |
| Q36120338 | Rapid detection of Lassa virus by reverse transcription-loop-mediated isothermal amplification |
| Q37201592 | Rat-atouille: A Mixed Method Study to Characterize Rodent Hunting and Consumption in the Context of Lassa Fever |
| Q55188128 | Re-emerging Lassa fever outbreaks in Nigeria: Re-enforcing "One Health" community surveillance and emergency response practice. |
| Q40873661 | Recent Lassa, Marbourg and Ebola viruses in African tropical viruses. I. Semiology--physiopathology--diagnosis--treatment (author's transl) |
| Q27485971 | Recent isolations of Lassa virus from Nigerian rodents |
| Q59350388 | Recombinant Lassa Virus Expressing Green Fluorescent Protein as a Tool for High-Throughput Drug Screens and Neutralizing Antibody Assays |
| Q50240250 | Recombinant monoclonal antibodies to the Lassa virus: the formation of reactive paratopes |
| Q46331411 | Recovery of a Lassa-related arenavirus in Zimbabwe. |
| Q39052889 | Replicon system for Lassa virus |
| Q45806207 | Reproduction of Lassa virus in different cell cultures |
| Q33317595 | Reproductive characteristics of Mastomys natalensis and Lassa virus prevalence in Guinea, West Africa |
| Q40721173 | Research with the Marburg, Lassa and Ebola viruses |
| Q125681023 | Reservoir displacement by an invasive rodent reduces Lassa virus zoonotic spillover risk |
| Q38993422 | Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa |
| Q41592314 | Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains |
| Q92255259 | Reverse genetics systems as tools to overcome the genetic diversity of Lassa virus |
| Q36905074 | Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice |
| Q34148663 | Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever |
| Q42600408 | Ribavirin for Lassa fever postexposure prophylaxis |
| Q43646600 | Ribavirin therapy for lassa fever. |
| Q43803702 | Ribonucleic acids of Machupo and Lassa viruses |
| Q33414102 | Risk maps of Lassa fever in West Africa |
| Q40352269 | Rodent host cell/Lassa virus interactions: evolution and expression of α-Dystroglycan, LARGE-1 and LARGE-2 genes, with special emphasis on the Mastomys genus |
| Q37252717 | Role of DC-SIGN in Lassa virus entry into human dendritic cells |
| Q38736122 | Role of LAMP1 Binding and pH Sensing by the Spike Complex of Lassa Virus |
| Q40481084 | Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. |
| Q38994875 | Role of the C terminus of Lassa virus L protein in viral mRNA synthesis |
| Q92019589 | Routine and pulse vaccination for Lassa virus could reduce high levels of endemic disease: A mathematical modelling study |
| Q40813777 | Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques |
| Q36970552 | Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates |
| Q56999457 | Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library |
| Q50240528 | Sedimentation analysis of the RNAs isolated from interfering particles of Lassa and Machupo viruses |
| Q40342577 | Sensitivity to ultraviolet radiation of Lassa, vaccinia, and Ebola viruses dried on surfaces |
| Q37097560 | Sensorineural hearing loss in Lassa fever: two case reports |
| Q39560352 | Sequence analysis of L RNA of Lassa virus |
| Q35229675 | Sequence variability and geographic distribution of Lassa virus, Sierra Leone |
| Q40262453 | Seroepidemiological study reveals regional co-occurrence of Lassa- and Hantavirus antibodies in Upper Guinea, West Africa |
| Q126009893 | Seroepidemiology of Lassa virus in pregnant women in Southern Nigeria: A prospective hospital-based cohort study |
| Q40811778 | Serological and biological evidence that Lassa-complex arenaviruses are widely distributed in Africa |
| Q36395853 | Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers |
| Q40725118 | Serological evidence of Lassa virus circulation in the Republic of Guinea |
| Q44372783 | Serological survey for the detection of antibodies to lassa virus in India |
| Q99550212 | Serosurvey on healthcare personnel caring for patients with Ebola virus disease and Lassa virus in the United States |
| Q35663703 | Shedding dynamics of Morogoro virus, an African arenavirus closely related to Lassa virus, in its natural reservoir host Mastomys natalensis |
| Q34360611 | Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects |
| Q40606288 | Short communication: Lassa fever in Sierra Leone: UN peacekeepers are at risk |
| Q45728790 | Signal peptide of Lassa virus glycoprotein GP-C exhibits an unusual length |
| Q40751030 | Simultaneous expression of the Lassa virus N and GPC genes from a single recombinant vaccinia virus |
| Q36021966 | Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein |
| Q45829724 | Some biochemical properties of Lassa virus RNA and polypeptides |
| Q36615566 | Spatial and temporal evolution of Lassa virus in the natural host population in Upper Guinea |
| Q24794317 | Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus |
| Q40797225 | Standardization of a plaque assay for Lassa virus |
| Q64360595 | Standardized focus assay protocol for biosafety level four viruses |
| Q38993418 | Strain-specific antibody response to Lassa virus in the local population of west Africa |
| Q45795867 | Structural and cell-associated proteins of Lassa virus |
| Q40054615 | Structural basis for antibody-mediated neutralization of Lassa virus |
| Q21134064 | Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease |
| Q115778667 | Structure and receptor recognition by the Lassa virus spike complex |
| Q56941600 | Structure of the Lassa virus glycan shield provides a model for immunological resistance |
| Q38924212 | Structure of the Lassa virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray scattering, and electron microscopy |
| Q27666703 | Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression |
| Q61798640 | Structure-activity relationship optimization for lassa virus fusion inhibitors targeting the transmembrane domain of GP2 |
| Q41922444 | Studies of Lassa Virus Cell Entry |
| Q50239327 | Studies on the binding modes of Lassa nucleoprotein complexed with m7GpppG and dTTP by molecular dynamic simulations and free energy calculations |
| Q40694925 | Study of certain indicators of immunity upon infecting CBA/Calac line mice with Lassa virus |
| Q27469223 | Surveillance of Lassa fever in missionaries stationed in West Africa |
| Q98620204 | Survival of Lassa Virus in Blood and Tissue Culture Media and in a Small Particle Aerosol |
| Q98730443 | Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-Saharan Africa |
| Q90399383 | Systematics, Ecology, and Host Switching: Attributes Affecting Emergence of the Lassa Virus in Rodents across Western Africa |
| Q33548699 | T cell-dependence of Lassa fever pathogenesis |
| Q90399761 | T-705-modified ssRNA in complex with Lassa virus nucleoprotein exhibits nucleotide splaying and increased water influx into the RNA-binding pocket |
| Q63246534 | T-Cell Response to Viral Hemorrhagic Fevers |
| Q55084398 | TIM-1 Mediates Dystroglycan-Independent Entry of Lassa Virus. |
| Q40492392 | Taking down Goliaths: new vaccines may spell the end for Ebola, Marburg and Lassa virus infections |
| Q50240016 | Teaching based on the case of Lassa fever. What ails our tropical medicine. Interview by Roland Knauer |
| Q33441299 | Temporal Progression of Lesions in Guinea Pigs Infected With Lassa Virus. |
| Q113274512 | Temporal analysis of Lassa virus infection and transmission in experimentally infected Mastomys natalensis |
| Q36818898 | The First Cases of Lassa Fever in Ghana |
| Q40885273 | The Lassa fever crisis |
| Q40888141 | The Lassa fever episode, Metro Toronto, August, 1976. |
| Q27486209 | The Lassa fever virus L gene: nucleotide sequence, comparison, and precipitation of a predicted 250 kDa protein with monospecific antiserum |
| Q33948025 | The Lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. |
| Q98384958 | The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry |
| Q56913187 | The S Genome Segment Is Sufficient to Maintain Pathogenicity in Intra-Clade Lassa Virus Reassortants in a Guinea Pig Model |
| Q92253323 | The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein |
| Q36146469 | The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset |
| Q44106205 | The challenges of detecting and responding to a Lassa fever outbreak in an Ebola-affected setting |
| Q90528649 | The chameleonic genetics of Lassa virus |
| Q50240286 | The comparative characteristics of the genetic traits of the Lassa and Mopeia viruses |
| Q40760636 | The cultivation and physicochemical properties of the Josiah strain of the Lassa virus |
| Q40658267 | The dynamics of the formation of IgG subclasses in Balb/c and CBA mice infected with the LCM, Lassa and Mopeia viruses and their role in diagnosis |
| Q40189592 | The exonuclease domain of Lassa virus nucleoprotein is involved in antigen-presenting-cell-mediated NK cell responses |
| Q40393878 | The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. |
| Q40779555 | The first imported case of Lassa fever in Japan |
| Q34102711 | The flexible C-terminal arm of the Lassa arenavirus Z-protein mediates interactions with multiple binding partners |
| Q99712926 | The function annotations of ST3GAL4 in human LAMP1 and Lassa virus GP-C interaction from the perspective of systems virology |
| Q46621136 | The immunogenic activity of the Lassa virus structural proteins |
| Q27302926 | The impact of human conflict on the genetics of Mastomys natalensis and Lassa virus in West Africa |
| Q50240371 | The indirect hemagglutination reaction for the detection of the Lassa virus |
| Q40762937 | The interferon-inducing activity of the Lassa virus in the body of inbred mice |
| Q50240224 | The isolation and characteristics of reassortants between the Lassa and Mopeia arenaviruses |
| Q43780899 | The isolation and characteristics of recombinant monoclonal antibodies to the Lassa virus |
| Q50240168 | The localization and preliminary characteristics of antigenic sites (B epitopes) in the nucleocapsid protein of the Lassa virus |
| Q39218301 | The microtubule motor protein KIF13A is involved in intracellular trafficking of the Lassa virus matrix protein Z. |
| Q40863379 | The nasty viruses--Lassa, Marburg, and Ebola |
| Q40920549 | The pathology of Lassa fever |
| Q27485964 | The pathology of human Lassa fever |
| Q50240228 | The production of antibody-producing hybridomas to the Lassa virus |
| Q40264454 | The proprotein convertase SKI-1/S1P. In vitro analysis of Lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors |
| Q40527288 | The public health response to a case of Lassa fever in London in 2000. |
| Q39481220 | The role of myristoylation in the membrane association of the Lassa virus matrix protein Z. |
| Q42415290 | The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP-C. |
| Q40179993 | The rubber plantation environment and Lassa fever epidemics in Liberia, 2008-2012: a spatial regression |
| Q36588064 | The search for animal models for Lassa fever vaccine development |
| Q36806151 | The sensitivity and specificity of Lassa virus IgM by ELISA as screening tool at early phase of Lassa fever infection |
| Q34448939 | The story of Lassa fever. Part I: Discovering the disease |
| Q40732837 | The story of Lassa fever. Part II: Learning more about the disease |
| Q39010237 | The story of Lassa fever. Part III: The disease in the community |
| Q39010233 | The story of Lassa fever. Part IV: The politics of research |
| Q40754017 | The therapeutic efficacy of ribamidil and virazole in experimental Lassa fever in monkeys |
| Q40934023 | The tragic story of the discovery of the Lassa fever virus |
| Q40830766 | The use of Lassa fever convalescent plasma in Nigeria |
| Q34394797 | Towards a human Lassa fever vaccine |
| Q27305228 | Transcriptional profiling of the circulating immune response to lassa virus in an aerosol model of exposure |
| Q34999818 | Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate |
| Q40901144 | Transport of a patient with Lassa fever in a Boeing 707 B |
| Q40092356 | Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies |
| Q40875673 | Tropical medicine. Lassa fever in Sierra Leone |
| Q37103833 | Uncoupling GP1 and GP2 expression in the Lassa virus glycoprotein complex: implications for GP1 ectodomain shedding |
| Q127616182 | Understanding Lassa virus |
| Q40040547 | Understanding the cryptic nature of Lassa fever in West Africa. |
| Q40514401 | Update on emerging infections: news from the Centers for Disease Control and Prevention. Imported Lassa fever--New Jersey, 2004. |
| Q58777764 | Use of Favipiravir to Treat Lassa Virus Infection in Macaques |
| Q56576756 | Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model |
| Q40846122 | Use of betapropionolactone inactivated Ebola, Marburg and Lassa intracellular antigens in immunofluorescent antibody assay. |
| Q40542683 | Use of guinea pigs for assessing the efficacy of vaccines against Lassa fever |
| Q40812305 | Use of monoclonal antibody for the detection of Lassa virus antibody and antigen in patients with Lassa fever |
| Q36630627 | Use of the complement fixation (CF) test in Lassa fever surveillance. Evidence for persistent CF antibodies |
| Q34888593 | Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of lassa fever |
| Q38823264 | Vaccine platforms to control Lassa fever |
| Q90440247 | Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot |
| Q40795237 | Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever |
| Q33723534 | VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever |
| Q34459935 | Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses |
| Q91021619 | Viral Hemorrhagic Fevers Other than Ebola and Lassa |
| Q40142154 | Viral evolution: The history of Lassa virus |
| Q34542167 | Viral haemorrhagic fevers caused by Lassa, Ebola and Marburg viruses |
| Q44089617 | Viral hemorrhagic fever--Ebola hemorrhagic fever, Marburg disease and Lassa fever |
| Q40518184 | Viral hemorrhagic fevers--Ebola hemorrhagic fever, Marburg virus disease, and Lassa fever |
| Q39609691 | Viral protein determinants of Lassa virus entry and release from polarized epithelial cells |
| Q24299858 | Virus entry. Lassa virus entry requires a trigger-induced receptor switch |
| Q63741077 | Virus⁻Host Interactions Involved in Lassa Virus Entry and Genome Replication |
| Q50420736 | What Pediatricians Should Know About Lassa Virus |
| Q44381329 | What is Lassa fever? |
| Q50239703 | Y chromosome STR haplotypes of Tibetan Living Tibet Lassa |
| Q35814851 | Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs |
| Q40433018 | Zidampidine, an aryl phosphate derivative of AZT: in vivo pharmacokinetics, metabolism, toxicity, and anti-viral efficacy against hemorrhagic fever caused by Lassa virus |
| Q40452524 | [Characterization of contacts of the population of Guinea with synanthropic rodents as Lassa fever virus carriers] |
| Q47846069 | [Lassa fever] |
| Q40883954 | [Lassa fever]. |
| Q40450196 | [Lassa fever]. |
| Q90159207 | [Lassa virus and myeloid dendritic cells: a privileged tropism for the suppression of the T lymphocyte response] |
| Q93811713 | [Lassa virus] |
| Q68881611 | [Lassa-fever a new dangerous virus infection] |
| Q98619162 | Morgan Brisse | field of work | P101 |
| Q706845 | Lassa fever | has cause | P828 |
| Category:Lassa virus | wikimedia |
Search more.